Corporate venturing units GV and SR One both reinvested as the hearing loss therapy developer pushed its overall funding past the $190m mark.

US-based hearing loss treatment developer Decibel Therapeutics completed an $82m series D round yesterday backed by GV and SR One, subsidiaries of internet and technology group Alphabet and pharmaceutical firm GlaxoSmithKline respectively.

Life sciences investment firm OrbiMed led the round, which included BlackRock Health Sciences, Casdin Capital, Janus Henderson, Samsara BioCapital, Surveyor Capital, Foresite Capital, S-Cubed Capital, Sobrato Capital, Third Rock Ventures and unnamed other investors.

Decibel is working on gene therapies intended to restore hearing loss or balance to…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.
Email LinkedIn